Inaugural Conference 2018
Inaugural Conference 2015
“FROM SCIENTIFIC BREAKTHROUGH TO PATIENT CARE”
Brussels, 10th November 2015
Auditorium Dupréel
ULB, Solbosch campus, 44 avenue Jeanne, 1050 Brussels
PROGRAM
8h45: Registration & welcome coffee
9h30: Welcome
Didier VIVIERS, Rector of ULB
Marco SCHETGEN, Dean of the Faculty of Medicine
Bruno VAN POTTELSBERGHE, Dean of Solvay Brussels School of Economics and Management
Michel GOLDMAN, Founder of the Institute for Interdisciplinary Innovation in healthcare (I3h)
Morning session: “Innovation for health”
Chairs: Eric DE KEULENEER, Chairman of the Board, ULB & Peter O’DONNELL, Associate Editor, Politico
|
10h00 – 10h20 |
Richard BERGSTROM, Director General, European Federation of Pharmaceutical Industries and Associations “Innovation for health: the commitment of the biopharmaceutical industry” |
| 10h20 – 10h40 | Sergio BONINI, Adviser, European Medecine Agency
“Innovation from a regulatory perspective” |
| 10h40 – 11h10 | Coffee break |
| 11h10 – 11h30 | Sander van DEVENTER, Managing Partner at Forbion Biocapital & Professor at Leiden University Medical Center “Financial incentives to boost innovation: what is needed?” |
| 11h30 – 11h50 | Jean-Louis VINCENT, President, World Federation of Societies of Intensive and Critical Care Medicine & Professor at ULB “Clinical trials: who is responsible for what ?” |
| 11h50 – 12h10 | Bettina RYLL, Founder, Melanoma Patient Network “A societal perspective: Time for changes !” |
| 12h10 – 13h00 | “Patient-centric innovation: what does it mean ?”
Round table introduced by Mary BAKER, President Year Of the Brain 2015, European Brain Council |
| 13h00 – 14h00 | Walking lunch |
Afternoon session: “Anti-TNF therapy, a paradigm for biopharmaceutical innovation”
Chairs: Michel GOLDMAN, I³h Founder & Sander van DEVENTER, Forbion Biocapital and Leiden University
| 14h00 – 14h30 | Bruce BEUTLER, Nobel Prize Laureate in Medicine 2011, University of Texas Southwestern Medical Center, USA “The discovery of new targets for inflammatory disorders” |
| 14h30 – 15h00 | Sir Marc FELDMANN, Laureate of Albert Lasker Award 2003, Kennedy Institute of Rheumatology, University of Oxford, UK “Pioneering anti-TNF therapy: lessons learned point path to future progress?” |
| 15h00 – 15h30 | Paul RUTGEERTS, Emeritus Professor of Medicine, KU Leuven “Targeting cytokines in inflammatory bowel disease: clinical research at the forefront” |
| 15h30 – 16h00 | Roch DOLIVEUX, Chairman of the Board at Vlerick Business School, retired CEO of UCB, and past-Chair of the IMI Governing Board “Bringing new biologicals to patients: the mission of the research-based pharmaceutical industry” |
| 16h00 – 16h30 | Coffee break |
| 16h30 – 17h30 | “What did we learn from the anti-TNF journey ?”
Round table introduced by Sander van DEVENTER & Mathias EVERS, Director, McKinsey |
| 17h30 | Cocktail-reception |
I3h INAUGURAL CONFERENCE
“FROM SCIENTIFIC BREAKTHROUGH TO PATIENT CARE”
Brussels, 10th November 2015
Auditorium Dupréel
ULB, Solbosch campus, 44 avenue Jeanne, 1050 Brussels
PROGRAM
8h45: Registration & welcome coffee
9h30: Welcome
Didier VIVIERS, Rector of ULB
Marco SCHETGEN, Dean of the Faculty of Medicine
Bruno VAN POTTELSBERGHE, Dean of Solvay Brussels School of Economics and Management
Michel GOLDMAN, Founder of the Institute for Interdisciplinary Innovation in healthcare (I3h)
Morning session: “Innovation for health”
Chairs: Eric DE KEULENEER, Chairman of the Board, ULB & Peter O’DONNELL, Associate Editor, Politico
|
10h00 – 10h20 |
Richard BERGSTROM, Director General, European Federation of Pharmaceutical Industries and Associations “Innovation for health: the commitment of the biopharmaceutical industry” |
| 10h20 – 10h40 | Sergio BONINI, Adviser, European Medecine Agency
“Innovation from a regulatory perspective” |
| 10h40 – 11h10 | Coffee break |
| 11h10 – 11h30 | Sander van DEVENTER, Managing Partner at Forbion Biocapital & Professor at Leiden University Medical Center “Financial incentives to boost innovation: what is needed?” |
| 11h30 – 11h50 | Jean-Louis VINCENT, President, World Federation of Societies of Intensive and Critical Care Medicine & Professor at ULB “Clinical trials: who is responsible for what ?” |
| 11h50 – 12h10 | Bettina RYLL, Founder, Melanoma Patient Network “A societal perspective: Time for changes !” |
| 12h10 – 13h00 | “Patient-centric innovation: what does it mean ?”
Round table introduced by Mary BAKER, President Year Of the Brain 2015, European Brain Council |
| 13h00 – 14h00 | Walking lunch |
Afternoon session: “Anti-TNF therapy, a paradigm for biopharmaceutical innovation”
Chairs: Michel GOLDMAN, I³h Founder & Sander van DEVENTER, Forbion Biocapital and Leiden University
| 14h00 – 14h30 | Bruce BEUTLER, Nobel Prize Laureate in Medicine 2011, University of Texas Southwestern Medical Center, USA “The discovery of new targets for inflammatory disorders” |
| 14h30 – 15h00 | Sir Marc FELDMANN, Laureate of Albert Lasker Award 2003, Kennedy Institute of Rheumatology, University of Oxford, UK “Pioneering anti-TNF therapy: lessons learned point path to future progress?” |
| 15h00 – 15h30 | Paul RUTGEERTS, Emeritus Professor of Medicine, KU Leuven “Targeting cytokines in inflammatory bowel disease: clinical research at the forefront” |
| 15h30 – 16h00 | Roch DOLIVEUX, Chairman of the Board at Vlerick Business School, retired CEO of UCB, and past-Chair of the IMI Governing Board “Bringing new biologicals to patients: the mission of the research-based pharmaceutical industry” |
| 16h00 – 16h30 | Coffee break |
| 16h30 – 17h30 | “What did we learn from the anti-TNF journey ?”
Round table introduced by Sander van DEVENTER & Mathias EVERS, Director, McKinsey |
| 17h30 | Cocktail-reception |
